Davidson Hamer, MD
Infectious Disease · Boston, MANPI 1790741841
Payments from drug & device makers
What this record shows
The money is spread across several categories — grants (48.2%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Bavarian Nordic A/s accounts for 60.3% of it on its own, with 5 other manufacturers making up the rest. 2025 is the largest year on record at $141,737, more than ten times the $2,945 reported in 2019. Among infectious disease clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 87 payments — averaging $2541.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bavarian Nordic A/s$133K
- Valneva USA, Inc.$39K
- Takeda Pharmaceuticals U.S.A., Inc.$38K
- Sanofi Pasteur Inc.$6K
- Valneva Austria GmbH$4K
- Emergent Biosolutions Inc.$124
Across 4 payments — averaging $22,738 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bavarian Nordic A/s$58K
- Sanofi Pasteur Inc.$31K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
What the payments were for
- Consulting fees$100,77546%
- Speaking & faculty fees$4,0012%
- Grants$106,64348%
- Travel & lodging$8,0094%
- Food & beverage$1,6581%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bavarian Nordic A/s | 16 | $133,382 |
| Valneva USA, Inc. | 38 | $39,410 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $38,110 |
| Sanofi Pasteur Inc. | 8 | $5,976 |
| Valneva Austria GmbH | 4 | $4,083 |
| Emergent Biosolutions Inc. | 1 | $124 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$221,086 in reported general payments places this provider in the 95th percentile of 368 infectious disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 12 | $48,022 |
| Naproxen | 12 | $252 |
| Losartan Potassium | 12 | $118 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Boston
- Yoav GolanBoston$1.1M
- Nesli BasgozBoston$901K
- Todd EllerinBoston$843K
- Paul SaxBoston$320K
- Camille KottonBoston$195K
- David SnydmanBoston$141K
- Eric RosenbergBoston$134K
- Deborah HungBoston$130K
- Laura KogelmanBoston$54K
- Jay FishmanBoston$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.